Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort.

Background: Upadacitinib was the first JAK-1 selective inhibitor registered for the treatment of moderate-to-severe atopic dermatitis (AD). Although efficacy and safety have been shown in clinical trials, real-world data on the use of upadacitinib in patients that have been treated with other immunosuppressants and targeted therapies is limited.

Objectives: To provide real-world evidence on the use of upadacitinib treatment in moderate-to-severe atopic dermatitis.

Home-Use Hyaluronic Acid Jet Injectors: Unreliable and Unsafe.

Background: Needle-free hyaluronic acid (HA) jet injectors are gaining popularity for rejuvenation treatment. The devices are widely available online and are used for self-injection or in beauty salons by nonphysicians. However, little is known about their performance and safety.

Clinical endpoints of needle-free jet injector treatment: An in depth understanding of immediate skin responses.

Objectives: Needle-free jet injectors have been used in dermatological practice for many years. However, predefined clinical endpoints that guide physicians to choose optimal device settings have not been clearly defined. Here, we evaluate immediate skin responses as clinical endpoints for needle-free jet injector treatments.